Neurological functions of the masterswitch protein kinase - Gsk-3

Frontiers in Molecular Neuroscience

Volumn , Issue APRIL, 2012, Pages

  Kaidanovich Beilin, Oksana ^a   Beaulieu, Jean Martin ^b   Jope, Richard Scott ^c   Woodgett, James Robert ^a,d  

^a MOUNT SINAI HOSPITAL   (Canada)

^b CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; SEROTONIN; TAU PROTEIN; WNT PROTEIN;

ALZHEIMER DISEASE; BIPOLAR DISORDER; BRAIN; BRAIN TUMOR; EDITORIAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FRAGILE X SYNDROME; GLYCOGEN SYNTHESIS; HUMAN; MOLECULAR CLONING; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; PROTEIN FUNCTION; SCHIZOPHRENIA; STROKE;

EID: 84864088625     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (22)

1. Beaulieu, J. M., Del'guidice, T., Sotnikova, T. D., Lemasson, M., and Gainetdinov, R. R. (2011). Beyond cAMP: the regulation of Akt and GSK3 by dopamine receptors. Front. Mol. Neurosci. 4:38. doi: 10.3389/ fnmol.2011.00038
2. Beurel, E. (2011). Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases. Front. Mol. Neurosci. 4:18. doi: 10.3389/ fnmol.2011.00018
3. Bradley, C. A., Peineau, S., Taghibiglou, C., Nicolas, C. S., Whitcomb, D. J., Bortolotto, Z. A., Kaang, B. K., Cho, K., Wang, Y. T., and Collingridge, G. L. (2012). A pivotal role of GSK-3 in synaptic plasticity. Front. Mol. Neurosci. 5:13. doi: 10.3389/ fnmol.2012.00013
4. Chuang, D. M., Wang, Z., and Chiu, C. T. (2011). GSK-3 as a target for lithium-induced neuroprotection against excitotoxicity in neuronal cultures and animal models of ischemic stroke. Front. Mol. Neurosci. 4:15. doi: 10.3389/fnmol.2011.00015
5. Cole, A. R. (2012). GSK3 as a sensor determining cell fate in the brain. Front. Mol. Neurosci. 5:4. doi: 10.3389/ fnmol.2012.00004
6. Eldar-Finkelman, H., and Martinez, A. (2011). GSK-3 inhibitors: preclini-cal and clinical focus on CNS. Front. Mol. Neurosci. 4:32. doi: 10.3389/ fnmol.2011.00032
7. Emamian, E. S. (2012). AKT/GSK3 signaling pathway and schizophrenia. Front. Mol. Neurosci. 5:33. doi: 10.3389/ fnmol.2012.00033
8. Freland, L., and Beaulieu, J. M. (2012). Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front. Mol. Neurosci. 5:14. doi: 10.3389/fnmol.2012.00014
9. Gomez-Sintes, R., Hernandez, F., Lucas, J. J., and Avila, J. (2011). GSK-3 mouse models to study neuronal apopto-sis and neurodegeneration. Front. Mol. Neurosci. 4:45. doi: 10.3389/ fnmol.2011.00045
10. Hanger, D. P., Hughes, K., Woodgett, J. R., Brion, J. P., and Anderton, B. H. (1992). Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of Tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett. 147, 58-62.
11. Jope, R. S. (2011). Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front. Mol. Neurosci. 4:16. doi: 10.3389/ fnmol.2011.00016
12. Kaidanovich-Beilin, O., and Woodgett, J. R. (2011). GSK-3: functional insights from cell biology and animal models. Front. Mol. Neurosci. 4:40. doi: 10.3389/fnmol.2011.00040
13. Kim, W. Y., and Snider, W. D. (2011). Functions of GSK-3 signaling in development of the nervous system. Front. Mol. Neurosci. 4:44. doi: 10.3389/ fnmol.2011.00044
14. Kim, Y. T., Hur, E. M., Snider, W. D., and Zhou, F. Q. (2011). Role of GSK3 signaling in neuronal morphogenesis. Front. Mol. Neurosci. 4:48. doi: 10.3389/fnmol.2011.00048
15. Kremer, A., Louis, J. V., Jaworski, T., and Van Leuven, F. (2011). GSK3 and Alzheimer's disease: facts and fiction. Front. Mol. Neurosci. 4:17. doi: 10.3389/fnmol.2011.00017
16. Medina, M., Garrido, J. J., and Wandosell, F. G. (2011). Modulation of GSK-3 as a therapeutic strategy on Tau pathologies. Front. Mol. Neurosci. 4:24. doi: 10.3389/fnmol.2011.00024
17. Mills, C. N., Nowsheen, S., Bonner, J. A., and Yang, E. S. (2011). Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors. Front. Mol. Neurosci. 4:47. doi: 10.3389/ fnmol.2011.00047
18. Mines, M. A., and Jope, R. S. (2011). Glycogen synthase kinase-3: a promising therapeutic target for Fragile X syndrome. Front. Mol. Neurosci. 4:35. doi: 10.3389/fnmol.2011.00035
19. Polter, A. M., and Li, X. (2011). Glycogen synthase kinase-3 is an intermediate modulator of serotonin neurotransmission. Front. Mol. Neurosci. 4:31. doi: 10.3389/ fnmol.2011.00031
20. Takahashi, M., Tomizawa, K., Kato, R., Sato, K., Uchida, T., Fujita, S. C., and Imahori, K. (1994). Localization and developmental changes of tau protein kinase I/glycogen synthase kinase-3 beta in rat brain. J. Neurochem. 63, 245-255.
21. Takashima, A. (2012). GSK-3 and memory formation. Front. Mol. Neurosci. 5:47. doi: 10.3389/fnmol.2012.00047
22. Valvezan, A. J., and Klein, P. S. (2012). GSK-3 and Wnt signaling in neurogenesis and bipolar disorder. Front. Mol. Neurosci. 5:1. doi: 10.3389/ fnmol.2012.00001